<DOC>
	<DOCNO>NCT01830270</DOCNO>
	<brief_summary>If surgery remain main treatment gastric cancer without distant metastasis ; perioperative-chemotherapy increase likelihood progression free survival . Perioperative chemotherapy appear many advantage : reduce tumor volume , improve R0 resection rate , act micro-metastases . Therefore , peri-operative chemotherapy combine cisplatin , epirubicin 5-Fluorouracile validate strategy treat gastric cancer . However , several pitfall remain . Particularly , 42 % patient could receive post-chemotherapy , due post-operative complication toxicity . To overcome limitation , investigator conduct phase II clinical trial assess clinical interest dose-dense preoperative chemotherapy combine cisplatin ( P ) , epirubicin ( E ) paclitaxel ( T ) . The increase evidence taxane 's role gastric cancer treatment , well biological synergism report paclitaxel/cisplatin paclitaxel/epirubicin combination , sustain development dose density base PET combination gastric carcinoma . The aim IPEC-GC study evaluate effectiveness PET preoperative regimen</brief_summary>
	<brief_title>Preoperative Dose-dense Chemotherapy With Weekly Cisplatin , Epirubicin Paclitaxel Treat Patients With Locally Gastric Cancer</brief_title>
	<detailed_description>The IPEC-GC study proof-of-concept study evaluate efficacy feasibility PET regimen 61 patient low oesophagus , oesophagus junction gastric carcinoma . Preoperative chemotherapy include eight weekly preoperative cycle cisplatin ( 30mg/m2 ) , epirubicin ( 50 mg/m2 ) paclitaxel ( 90 mg/m2 ) break one week without chemotherapy cycle 4 5 . Surgery perform within 4-6 week end last cycle chemotherapy . Primary endpoint trial curative resection rate ( =R0 ) . R0 must higher 79 % achieve previous publish study . Response rate , histologic response rate ( Becker score ) , progression-free survival , overall survival , impact complete response survival dose-density secondary endpoint . For ancillary study , tumor ( biopsy operative specimen ) serum collect identify biomarkers correlate treatment efficacy . This study carry Besançon University Hospital approve independent Est-II ethic committee French National Authority Health : AFSSAPS .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Inclusion criterion : Age &gt; 18 &lt; 70 year ( male female ) surgical resectability ECOG performance status ≤ 1 ASA score &lt; 3 ( appreciation surgeon ) BMI &lt; 30 upper oesogastrectomy require previous cytotoxic chemotherapy ejection fraction &gt; 50 % echocardiography start therapy write informed consent Noninclusion criterion : distant metastases infiltration adjacent structure organ primarily resectable stage relapse hypersensitivity Paclitaxel , Epirubicin Cisplatin malignant secondary disease , date back &lt; 5 year ( exception : situ carcinoma cervix uterus , adequately treat skin basal cell carcinoma ) peripheral polyneuropathy diabetes complicate coronary artery disease vasculopathy Severe respiratory insufficiency patient weight loss &gt; 10 % pregnancy lactation inclusion another trial patient medical psychiatric condition disease would make patient inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>medical oncology</keyword>
	<keyword>chemotherapy optimization</keyword>
	<keyword>dose density</keyword>
</DOC>